Plain-English translation of NCT07364474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying how your body's immune system reacts to a treatment called melphalan delivered directly to tumors in your liver. Melphalan is a cancer-fighting drug, and in this study it's given through a special procedure that targets liver metastases (cancer spots that have spread from your eye). Researchers want to understand how this treatment affects your immune response by comparing blood and tissue samples taken before and after the procedure.
Eye melanoma that has spread to the liver is a serious condition, and doctors want to find better ways to treat it. By studying how your immune system responds to this medication, researchers hope to understand whether the treatment works by helping your body fight the cancer, and whether this approach could help future patients.
You likely qualify if…
You likely don't qualify if…
You will have a baseline visit where blood samples and a tissue biopsy are collected from your liver tumor. Then you will receive the treatment—a single dose of the medication delivered directly to your liver tumors through a special catheter procedure. About 3–4 weeks later, you'll return for a follow-up visit where additional blood samples and another tissue biopsy will be taken. The study compares these before-and-after samples to measure how your immune system responded to the treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Sponsor
Massachusetts General Hospital
Enrollment target
~10 participants
Started
January 2026
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Aleigha Lawless
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.